Publications en collaboration avec des chercheurs de Fundación Hospital Alcorcón (18)

2024

  1. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  2. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  3. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics

  4. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  4. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

2019

  1. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

    Current Medical Research and Opinion, Vol. 35, Núm. 7, pp. 1297-1304

2017

  1. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

2016

  1. Current concepts on microscopic colitis: Evidence-based statements and recommendations of the Spanish Microscopic Colitis Group

    Alimentary Pharmacology and Therapeutics, Vol. 43, Núm. 3, pp. 400-426

2015

  1. Incidence, management, and course of cancer in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333

2012

  1. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

    Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523

2010

  1. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study

    Journal of Crohn's and Colitis, Vol. 4, Núm. 6, pp. 629-636